Upsher-Smith adds 2 near-term generics
Upsher-Smith has added two near-term generic products to its portfolio in an exclusive agreement with CorePharma.
CorePharma will secure FDA approval and manufacture both products at its New Jersey manufacturing facility. Upon FDA approval, Upsher-Smith will market and distribute the products under its own label in the United States.
This collaboration supports Upsher-Smith’s company-wide effort to grow the company’s portfolio of products through strategic partnerships and product acquisitions, Upsher-Smith said.
[Read more: Upsher-Smith intros three new dosage strengths for generic Absorica]
“Our partnership with CorePharma, a leader in product development and manufacturing, is especially significant as it provides Upsher-Smith with two near-term product opportunities that will help maximize top-line revenue in FY2022,” said Arun Nataraj, vice president of corporate development at Upsher-Smith. “This is the latest of four recently completed strategic partnerships, reflecting the rapid execution of our external development strategy to expand our generic portfolio.”
Rich Fisher, president and chief operating officer of Upsher-Smith added, “Over the past six months, our corporate development team has had great success expanding our portfolio of high-quality generic products and positioning Upsher-Smith for both near-term and future growth. We look forward to a productive partnership with CorePharma.”
[Read more: Upsher-Smith, Emphascience ink deal for specialty branded generic product]
“CorePharma is extremely happy to partner with a world class organization such as Upsher-Smith,” said Arpit Patel, CEO of CorePharma. “With their strong commercial experience in the U.S. market, we are confident of the success of these product launches and are looking forward to expanding our partnership across many other future opportunities.”